

Anti-IL-6/IFN γ 2 Antibody (Elsilimomab)

Introduction

Elsilimomab (B-E8) is an anti-interleukin-6 (IL-6) IgG1 monoclonal antibody with a KD of 22 pM and an IC₅₀ of 1.4 nM. Elsilimomab can be used in the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA).

Product parameters

Alternative Names	BE-8, Elsilimomab
Target Accession	P05231
Target	IL-6 / IFN γ 2
CAS number	468715-71-1
Molecular Weight	145 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IL-6 His at 2 ug/mL can bind Anti-IL-6/IFN γ 2 Antibody (Elsilimomab), EC ₅₀ =0.0162 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

